Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrorelix-mediated luteolysis for hemorrhagic corpus luteum
2008-002680-13Phase 2Terminated
- Sponsor
- Fundación para la Investigación del Hospital Universitario Doctor Peset
- Start
- Mar 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetrorelix in Corpus luteum hematoma and corpus luteum cyst, sponsored by Fundación para la Investigación del Hospital Universitario Doctor Peset. Primary endpoints: Serum progesterone, Corpus luteum vascularization on Doppler ultrasound and 4 more. Started Mar 2009; status: terminated.
02
Drugs
cetrorelix
03
Conditions
Corpus luteum hematomacorpus luteum cyst
Beyond the preview
Go deeper on 2008-002680-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002680-13.